UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000049607 |
|---|---|
| Receipt number | R000056501 |
| Scientific Title | Special drug use-results surveillance <Patients with cold agglutinin disease> |
| Date of disclosure of the study information | 2022/11/25 |
| Last modified on | 2026/06/02 10:43:13 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Special drug use-results surveillance
<Patients with cold agglutinin disease>
Acronym
Special drug use-results surveillance
<Patients with cold agglutinin disease>
Scientific Title
Special drug use-results surveillance
<Patients with cold agglutinin disease>
Scientific Title:Acronym
Special drug use-results surveillance
<Patients with cold agglutinin disease>
Region
| Japan |
Condition
Condition
Cold agglutinin disease
Classification by specialty
| Medicine in general | Hematology and clinical oncology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To collect information on safety and efficacy of sutimlimab for patients with cold agglutinin disease (Cold agglutinin disease; CAD) under actual conditions of use.
Basic objectives2
Safety
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Safety (Adverse Drug Reaction)
Key secondary outcomes
Efficacy
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
The target population of interest is patients with CAD treated with sutimlimab, but all patients treated with sutimlimab are included.
Key exclusion criteria
NA
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | PMS Control Officer |
| Middle name | |
| Last name | PMS Control Officer |
Organization
Recordati Rare Diseases Japan K.K.
Division name
Post-Marketing Surveillance Department
Zip code
107-0052
Address
Akasaka JEBL, Akasaka, Minato-ku, Tokyo
TEL
03-4510-2910
rrdj_pms@recordati.com
Public contact
Name of contact person
| 1st name | Recordati Rare Diseases Japan K.K. |
| Middle name | |
| Last name | Recordati Rare Diseases Japan K.K. |
Organization
Recordati Rare Diseases Japan K.K.
Division name
Post-Marketing Surveillance Department
Zip code
107-0052
Address
Akasaka JEBL, Akasaka, Minato-ku, Tokyo
TEL
03-4510-2910
Homepage URL
rrdj_pms@recordati.com
Sponsor or person
Institute
Recordati Rare Disease Japan K.K.
Institute
Department
Personal name
Funding Source
Organization
Recordati Rare Diseases Japan K.K.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Recordati Rare Diseases Japan K.K.
Address
Akasaka JEBL, Akasaka, Minato-ku, Tokyo
Tel
03-4510-2910
rrdj_pms@recordati.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2022 | Year | 11 | Month | 25 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Enrolling by invitation
Date of protocol fixation
| 2022 | Year | 05 | Month | 13 | Day |
Date of IRB
| 2022 | Year | 11 | Month | 18 | Day |
Anticipated trial start date
| 2022 | Year | 11 | Month | 08 | Day |
Last follow-up date
| 2026 | Year | 04 | Month | 28 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Special Drug Use-result surveillance for all cases
Management information
Registered date
| 2022 | Year | 11 | Month | 25 | Day |
Last modified on
| 2026 | Year | 06 | Month | 02 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056501
